NEW YORK (GenomeWeb News) – 23andMe has been hit with a class action lawsuit just a few days after the US Food and Drug Administration told the firm that it must stop marketing its spit test and genome service to consumers because it has failed to address FDA's questions about the clinical and analytical validity of the product.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.